Published in Nat Biotechnol on June 07, 2012
Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat Biotechnol (2013) 1.97
Long noncoding RNAs: fresh perspectives into the RNA world. Trends Biochem Sci (2013) 1.55
Managing diabetes with nanomedicine: challenges and opportunities. Nat Rev Drug Discov (2014) 1.39
Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle. Proc Natl Acad Sci U S A (2013) 1.08
pH-dependent anticancer drug release from silk nanoparticles. Adv Healthc Mater (2013) 0.99
Design considerations for nanotherapeutics in oncology. Nanomedicine (2015) 0.96
Photoresponsive nanoparticles for drug delivery. Nano Today (2015) 0.89
Fabrication of micropatterned polymeric nanowire arrays for high-resolution reagent localization and topographical cellular control. Nano Lett (2015) 0.87
Computational nanomedicine: modeling of nanoparticle-mediated hyperthermal cancer therapy. Nanomedicine (Lond) (2013) 0.81
Nanobiomotors of archaeal DNA repair machineries: current research status and application potential. Cell Biosci (2014) 0.80
Synthesis of linear and cyclic peptide-PEG-lipids for stabilization and targeting of cationic liposome-DNA complexes. Bioorg Med Chem Lett (2016) 0.79
Superparamagnetic reconstituted high-density lipoprotein nanocarriers for magnetically guided drug delivery. Int J Nanomedicine (2017) 0.79
Real-time imaging of the epithelial-mesenchymal transition using microRNA-200a sequence-based molecular beacon-conjugated magnetic nanoparticles. PLoS One (2014) 0.78
Delivery of host cell-directed therapeutics for intracellular pathogen clearance. Expert Rev Anti Infect Ther (2013) 0.78
Cooperative transmembrane penetration of nanoparticles. Sci Rep (2015) 0.76
Modelling the effect of SPION size in a stent assisted magnetic drug targeting system with interparticle interactions. ScientificWorldJournal (2015) 0.76
Differential bioreactivity of neutral, cationic and anionic polystyrene nanoparticles with cells from the human alveolar compartment: robust response of alveolar type 1 epithelial cells. Part Fibre Toxicol (2015) 0.75
Imaging the pharmacology of nanomaterials by intravital microscopy: Toward understanding their biological behavior. Adv Drug Deliv Rev (2016) 0.75
Formation of nanoparticles by cooperative inclusion between (S)-camptothecin-modified dextrans and β-cyclodextrin polymers. Beilstein J Org Chem (2015) 0.75
Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med (2012) 5.92
Combinatorial synthesis of chemically diverse core-shell nanoparticles for intracellular delivery. Proc Natl Acad Sci U S A (2011) 1.46
Biologics inch toward cholesterol-lowering market. Nat Biotechnol (2012) 1.21
Bottom-up design and synthesis of limit size lipid nanoparticle systems with aqueous and triglyceride cores using millisecond microfluidic mixing. Langmuir (2012) 1.13
SGLT2 inhibitors race to enter type-2 diabetes market. Nat Biotechnol (2012) 2.02
First CRISPR-Cas patent opens race to stake out intellectual property. Nat Biotechnol (2014) 1.81
Report claims no yield advantage for Bt crops. Nat Biotechnol (2009) 1.78
New class PCSK9 blockers stride into cholesterol market. Nat Biotechnol (2015) 1.70
Gene therapy finds its niche. Nat Biotechnol (2011) 1.70
Biogen and UPenn join forces to commercialize gene therapies. Nat Biotechnol (2016) 1.56
Report blames GM crops for herbicide spike, downplays pesticide reductions. Nat Biotechnol (2010) 1.52
EGFR inhibitors embrace KRAS. Nat Biotechnol (2008) 1.45
FDA approves 'farmaceutical' drug from transgenic chickens. Nat Biotechnol (2016) 1.39
Nature Biotechnology's academic spinouts of 2016. Nat Biotechnol (2017) 1.38
Next generation flu vaccine boosted by Chiron debacle. Nat Biotechnol (2004) 1.38
CAR-T cells forge ahead, Novartis reorganizes. Nat Biotechnol (2016) 1.28
Amgen swallows Micromet to BiTE into ALL market. Nat Biotechnol (2012) 1.27
Immune-checkpoint inhibitors march on, now in combinations. Nat Biotechnol (2014) 1.23
First Axl inhibitor enters clinical trials. Nat Biotechnol (2013) 1.22
Firms combine experimental cancer drugs to speed development. Nat Biotechnol (2010) 1.22
FDA approvals usher in the post-interferon era in HCV. Nat Biotechnol (2014) 1.18
New Merck and Vertex drugs raise standard of care in hepatitis C. Nat Biotechnol (2011) 1.17
Amgen's bispecific antibody puffs across finish line. Nat Biotechnol (2015) 1.17
TeGenero fiasco prompts regulatory rethink. Nat Biotechnol (2006) 1.16
Duchenne muscular dystrophy drugs at the crossroads, as newer agents advance. Nat Biotechnol (2016) 1.13
Companies in rapid pursuit of Btk immunokinase. Nat Biotechnol (2012) 1.08
Cautious optimism surrounds early clinical data for PD-1 blocker. Nat Biotechnol (2012) 1.07
Fresh from the biologic pipeline-2009. Nat Biotechnol (2010) 1.05
Amgen punts on deCODE's genetics know-how. Nat Biotechnol (2013) 1.05
Phase 3 data for PCSK9 inhibitor wows. Nat Biotechnol (2013) 1.04
Big oil turns on biofuels. Nat Biotechnol (2013) 1.01
Genentech raises stakes on PARP inhibitors. Nat Biotechnol (2006) 1.01
Milestone approval lifts Illumina's NGS from research into clinic. Nat Biotechnol (2014) 0.97
Can 'double blockbuster' strengthen Amgen's backbone? Nat Biotechnol (2008) 0.95
Amgen's angiopoietin blocker fails in ovarian cancer. Nat Biotechnol (2015) 0.94
Tysabri raises alarm bells on drug class. Nat Biotechnol (2005) 0.93
First approval in sight for Novartis' CAR-T therapy after panel vote. Nat Biotechnol (2017) 0.92
Doubts surround link between Bt cotton failure and farmer suicide. Nat Biotechnol (2009) 0.91
Doubts raised over 'read-through' Duchenne drug mechanism. Nat Biotechnol (2013) 0.91
Pivotal trials for β-secretase inhibitors in Alzheimer's. Nat Biotechnol (2015) 0.90
J&J's billion dollar punt on anti-amyloid antibody. Nat Biotechnol (2009) 0.87
Apple moves on health, drug developers shift into smart gear. Nat Biotechnol (2014) 0.87
Illumina claims $1,000 genome win. Nat Biotechnol (2014) 0.87
Amgen announces oncolytic virus shrinks tumors. Nat Biotechnol (2013) 0.85
Commercial interest grows in glycan analysis. Nat Biotechnol (2007) 0.84
IDO inhibitors move center stage in immuno-oncology. Nat Biotechnol (2015) 0.83
Recasting natural product research. Nat Biotechnol (2012) 0.83
Small molecule challenges dominance of TNF-alpha inhibitors. Nat Biotechnol (2008) 0.83
Third Tysabri adverse case hits drug class. Nat Rev Drug Discov (2005) 0.83
First oncolytic virus edges towards approval in surprise vote. Nat Biotechnol (2015) 0.83
Omics-driven startups challenge healthcare model. Nat Biotechnol (2015) 0.82
Genentech obtains proof of concept for hedgehog inhibition. Nat Biotechnol (2009) 0.82
Glial cells on the radar. Nat Biotechnol (2009) 0.82
Bad medicine. Nat Biotechnol (2007) 0.82
Investors start backing hearing loss treatments. Nat Biotechnol (2013) 0.82
Calamitous HCV trial casts shadow over nucleoside drugs. Nat Biotechnol (2012) 0.82
Footrace to clinic heats up for T-cell nuclear receptor inhibitors. Nat Biotechnol (2013) 0.82
Pharma consolidates its grip on post-antibody landscape. Nat Biotechnol (2007) 0.81
EU to review rare disease drugs market exclusivity. Nat Biotechnol (2004) 0.81
Exosome cancer diagnostic reaches market. Nat Biotechnol (2016) 0.80
Genentech to salvage anti-MET antibody with subgroup analysis. Nat Biotechnol (2014) 0.80
Antibiotics au naturel. Nat Biotechnol (2006) 0.80
Industry pursues co-stimulatory receptor immunomodulators to treat cancer. Nat Biotechnol (2013) 0.79
First integrin inhibitor since Tysabri nears approval for IBD. Nat Biotechnol (2014) 0.79
Kenyan dispute illuminates bioprospecting difficulties. Nat Biotechnol (2004) 0.79
Cardiac stem cell therapies inch toward clinical litmus test. Nat Biotechnol (2013) 0.79
Making green. Nat Biotechnol (2009) 0.78
Positive clinical data in Parkinson's and ischemia buoy gene therapy. Nat Biotechnol (2007) 0.78
Second oral MS drug wins FDA nod. Nat Biotechnol (2013) 0.78
Protein chip companies turn to biomarkers. Nat Biotechnol (2005) 0.78
CETP inhibitors boost 'good' cholesterol to no avail. Nat Biotechnol (2016) 0.78
Antiinfective biotechs face partnering gap. Nat Biotechnol (2005) 0.78
First generic biologics finally approved. Nat Rev Drug Discov (2006) 0.78
Despite slow progress, bispecifics generate buzz. Nat Biotechnol (2016) 0.77
RaNA therapeutics. Nat Biotechnol (2012) 0.77
Monoclonal T-cell receptor drugs pique pharma's interest. Nat Biotechnol (2013) 0.77
Cancer centers zero in on exceptional responders. Nat Biotechnol (2014) 0.77
Merck's statin first to receive over-the-counter status. Nat Rev Drug Discov (2004) 0.76
First cystic fibrosis drug advances towards approval. Nat Biotechnol (2011) 0.76
EPO neem patent revocation revives biopiracy debate. Nat Biotechnol (2005) 0.76
Drug developers refocus efforts on RAS. Nat Biotechnol (2016) 0.76
Insomniacs get new mechanism sleep drug Belsomra. Nat Biotechnol (2014) 0.76
First-in-class cancer therapeutic to stimulate natural killer cells. Nat Biotechnol (2006) 0.76
Fast track to MS drug. Nat Biotechnol (2004) 0.76
The business of making vaccines. Nat Biotechnol (2005) 0.76
Anti-CD20 antibody wows in multiple sclerosis. Nat Biotechnol (2015) 0.76
Cimzia's setback paves way for other TNF inhibitors in Crohn's disease. Nat Biotechnol (2007) 0.76
Drug makers target ubiquitin proteasome pathway anew. Nat Biotechnol (2015) 0.76
Stem cell therapy clears first hurdle in AMD. Nat Biotechnol (2014) 0.76
Drugmakers plow more resources into autism. Nat Biotechnol (2013) 0.75
Grail to pour $1 billion into blood test to detect early cancer. Nat Biotechnol (2017) 0.75
Immuno-oncology moves beyond PD-1. Nat Biotechnol (2015) 0.75
Belgian biotech's clot-buster approved for aging eyes. Nat Biotechnol (2012) 0.75
Flu vaccine makers upgrade technology--and pray for time. Nat Biotechnol (2009) 0.75
Vaccine market boosters. Nat Biotechnol (2009) 0.75
Abbott outbids Biogen for Facet's multiple sclerosis antibody. Nat Biotechnol (2010) 0.75
Industry continues dabbling with open innovation models. Nat Biotechnol (2011) 0.75
Pertuzumab to bolster Roche/Genentech's breast cancer franchise? Nat Biotechnol (2011) 0.75
Synthetic biology firms pivot from biofuels to cheap biologics. Nat Biotechnol (2016) 0.75
Roche backs Aileron's stapled peptides. Nat Biotechnol (2010) 0.75
National Academies relax stance on germline edits. Nat Biotechnol (2017) 0.75
Safety profiles come to fore as more drugs approach MS market. Nat Biotechnol (2012) 0.75
Firms chase diabetic inflammation with anti-IL-1beta antibodies. Nat Biotechnol (2010) 0.75
Big oil bucks for algae. Nat Biotechnol (2009) 0.75